Loading...
XSTO
KLAR
Market cap6mUSD
Jun 23, Last price  
0.43SEK
1D
-2.52%
1Q
-65.08%
Jan 2017
-94.99%
IPO
-91.39%
Name

Klaria Pharma Holding AB (publ)

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
27.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
30.26%
Rev. gr., 5y
-11.85%
Revenues
2m
0002,275,000649,0004,223,0007,220,0006,112,0005,868,00002,248,000
Net income
-48m
L+33.44%
0-5,593,000-14,550,000-12,014,000-27,306,000-23,843,000-51,439,000-53,534,000-63,774,000-35,784,000-47,750,000
CFO
-12m
L+31.76%
-4,429,000-14,393,000-12,060,000-9,126,000-14,796,000-35,296,000-24,797,000-49,729,000-9,058,000-11,935,000

Profile

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
URL
https://www.klaria.com/
IPO date
Oct 21, 2015
Employees
6
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,248
 
5,868
-3.99%
Cost of revenue
33,533
14,902
61,511
Unusual Expense (Income)
NOPBT
(31,285)
(14,902)
(55,643)
NOPBT Margin
Operating Taxes
18
(57)
117
Tax Rate
NOPAT
(31,303)
(14,845)
(55,760)
Net income
(47,750)
33.44%
(35,784)
-43.89%
(63,774)
19.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
(18)
16,371
41,734
BB yield
0.04%
-35.15%
-61.92%
Debt
Debt current
18,932
16,743
Long-term debt
1,359
Deferred revenue
Other long-term liabilities
619
Net debt
(598)
17,685
1,341
Cash flow
Cash from operating activities
(11,935)
(9,058)
(49,729)
CAPEX
(42)
Cash from investing activities
(2)
(42)
Cash from financing activities
11,272
(6,457)
41,056
FCF
76,926
(72,985)
(55,107)
Balance
Cash
598
1,247
16,761
Long term investments
Excess cash
486
1,247
16,468
Stockholders' equity
(45,339)
(237,874)
(96,957)
Invested Capital
49,263
297,940
189,750
ROIC
ROCE
EV
Common stock shares outstanding
124,620
100,798
58,102
Price
0.34
-27.49%
0.46
-60.17%
1.16
-81.20%
Market cap
41,748
-10.35%
46,569
-30.91%
67,398
-80.23%
EV
41,148
64,256
68,763
EBITDA
(20,066)
(14,893)
(44,609)
EV/EBITDA
Interest
3,777
7,843
Interest/NOPBT